NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death…
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of…
MS Canada’s cycling fundraising event series is back this June featuring road bike tours across 12 Canadian communities, bringing people…
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- MS Canada, the country’s leading organization in multiple sclerosis (MS) research and advocacy…
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part…
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates,…
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted…
MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic…
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May…